138642-94-1

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 4-cyano-3-ethyl-, is used as a precursor in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
Benzoic acid, 4-cyano-3-ethylis also utilized in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used in Organic Chemistry:
Benzoic acid, 4-cyano-3-ethyl-, serves as a reagent in organic chemistry, facilitating various chemical reactions and synthesis processes.
Used in Dye and Perfume Manufacturing:
Due to its chemical properties, Benzoic acid, 4-cyano-3-ethyl- is used in the manufacture of dyes and perfumes, contributing to the creation of vibrant colors and fragrant scents.
Used as a Preservative in Food and Beverage Industry:
Benzoic acid, 4-cyano-3-ethyl-, is used as a preservative in food and beverages due to its antimicrobial properties. It helps maintain the freshness and quality of products by inhibiting the growth of microorganisms.

Upstream product

• 744200-38-2 4-bromo-2-ethylbenzonitrile 
• 124-38-9 carbon dioxide 

Downstream Products

• 1092844-19-3 C₂₀H₂₀N₂O 

Relevant academic research and scientific papers

New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists

Vasopressin (AVP) is a hormone that stimulates an increase in water permeability through activation of V2 receptors in the kidney. The analogue of AVP, desmopressin, has proven an effective drug for diseases where a reduction of urine output is desired. However, its peptidic nature limits its bioavailability. We report herein the discovery of potent, nonpeptidic, benzylurea derived agonists of the vasopressin V2 receptor. We describe substitutions on the benzyl group to give improvements in potency and subsequent modifications to the urea end group to provide improvements in solubility and increased oral efficacy in a rat model of diuresis. The lead compound 20e (VA106483) is reported for the first time and has been selected for clinical development.

benzamide derivatives as oxytocin agonists and vasopressin antagonists

Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or Via receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.